Riddhi Siddhi Gluco Biols Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Riddhi Siddhi Gluco Biols Ltd trades at ₹730, in a confirmed uptrend and 10 weeks into that stage. That is +19.9% against its own 200-day average. It sits at 77% of a 52-week range of ₹411 to ₹823. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 3 straight weeks.

Today the stock is in a confirmed uptrend — week 10 of stage 2, confirmed. At ₹730 it trades +19.9% versus its 200-day average and sits at 77% of its 52-week range (₹411–₹823).

Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +142% while the NIFTY 500 moved +252% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 3 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 95th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Riddhi Siddhi Gluco Biols Ltd trades at 26.0× P/E, at the pricey end of its own range (95th percentile). Its long-run median P/E is 8.3×, measured across 9.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 26.0× is at the pricey end of its own range (95th percentile), against a long-run median of 8.3× measured over 9.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

The price move, decomposed: over 10y, of the +8.9%/yr price move, ~−6.6%/yr came from earnings growth and ~+15.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Riddhi Siddhi Gluco Biols Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 10 quarters across 3 curves, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

44.6/100 — rank 26 of 48 in Trading · 79% evidence confidence

Riddhi Siddhi Gluco Biols Ltd scores 44.6 out of 100 against the 48 companies it is compared with in Trading, ranking 26. Price leads the evidence: RS versus the benchmark is 27.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.

The four contributions add to the total exactly: 12.3 + 8.9 + 7 + 16.4 = 44.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Riddhi Siddhi Gluco Biols Ltd reported ₹9.0 Cr of revenue in the Mar 26 quarter, −67.9% year on year. Over 10 years it has compounded at −3.6% a year. The last full year, FY26, came in at ₹236 Cr. The last four reported quarters add to ₹236 Cr.

Riddhi Siddhi Gluco Biols Ltd reported ₹9.0 Cr of revenue in the Mar 26 quarter, −67.9% year on year. Over 10 years it has compounded at −3.6% a year. The last full year, FY26, came in at ₹236 Cr. The last four reported quarters add to ₹236 Cr.

FY26 revenue came in at ₹236 Cr (+73.5% on the year), capping 10 years at −3.6% compound. The latest quarter (Mar 26) printed ₹9.0 Cr, −67.9% year on year.

Pace check: the last four quarters averaged +223.8% growth against the decade's −3.6% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +74.8% over the last 4 quarters against −6.3%/yr over the last 8 — accelerating.

→ Revenue slipped — did margins hold as it scaled? Next: −89.0% this quarter (−77.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Riddhi Siddhi Gluco Biols Ltd's operating margin is −89.0% in the Mar 26 quarter, −77.0 percentage points against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged −9.0% to 13.0%. The current quarter is running below every full year in that window.

Riddhi Siddhi Gluco Biols Ltd's operating margin is −89.0% in the Mar 26 quarter, −77.0 percentage points against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged −9.0% to 13.0%. The current quarter is running below every full year in that window.

The latest quarter's operating margin is −89.0%, −77.0 pp against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged −9.0%–13.0%.

🚨 Why the margin moved: operating margin went −76.6 pp year on year while gross margin went +14.7 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

→ Margins slipped — did that reach the bottom line? Next: profit −760.0% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Riddhi Siddhi Gluco Biols Ltd posted a net loss of ₹33.0 Cr in the Mar 26 quarter. That quarter carries a one-off item larger than its own revenue, so the year-on-year figure is an artefact rather than a trading result. The full FY26 year was a loss of ₹12.0 Cr. That loss is 366.7% of the quarter's revenue.

Riddhi Siddhi Gluco Biols Ltd posted a net loss of ₹33.0 Cr in the Mar 26 quarter. That quarter carries a one-off item larger than its own revenue, so the year-on-year figure is an artefact rather than a trading result. The full FY26 year was a loss of ₹12.0 Cr. That loss is 366.7% of the quarter's revenue.

Mar 26 profit was ₹−33.0 Cr, −760.0% year on year. On the full year, FY26 printed ₹−12.0 Cr (null).

🚨 Read this profit with care: at ₹−33.0 Cr it is larger than the whole quarter's revenue of ₹9.0 Cr — no operating business earns more than it sells, so this is a one-off item (a debt-to-equity conversion, a tax write-back or an asset sale), not money the business earned. The underlying operations are running at −89.0% operating margin; the year-on-year jump and any P/E built on this number are artefacts of the one-off, not a real earnings turn.

→ Profit rose — but did the cash follow? Next: 409% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 409% of Riddhi Siddhi Gluco Biols Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹−9.0 Cr of operating cash against ₹−12.0 Cr of profit. After ₹0.0 Cr of capital spending, ₹−9.0 Cr was left as free cash.

FY26: operating cash of ₹−9.0 Cr against reported profit of ₹−12.0 Cr, leaving free cash of ₹−9.0 Cr after ₹0.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 409% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 409%: the cash cycle tightened 146 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 2.2× depreciation over three years, so the next section's job is to check what that build-out is buying.

→ So follow the cash to where it goes. Next: ₹62.0 Cr of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Riddhi Siddhi Gluco Biols Ltd's cash conversion cycle runs 65 days in FY26, down from 211 days in FY21. Capital spending ran ₹62.0 Cr over the last 3 years. At FY26 sales of ₹236 Cr each day of that cycle holds about ₹0.6 Cr, so roughly ₹42.0 Cr sits inside the business at any moment.

FY26: debtors at 13 days, inventory at 78 days — roughly 2.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 65 days, tighter than FY21's 211.

The full loop: cash goes out to suppliers and production on day 0; stock waits 78 days to sell; customers pay about 13 days after that; and suppliers themselves are paid at 25 days — netting out to the 65-day cycle.

In money terms: at FY26 sales of ₹236 Cr, each day of the cycle holds about ₹0.6 Cr — so the 65-day loop keeps roughly ₹42.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹62.0 Cr over the last 3 fiscal years against ₹28.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 3%.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Riddhi Siddhi Gluco Biols Ltd earns a ROCE of 3% in FY26. That is up from a trough of 0% in FY21. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is −5.1% net margin on 0.12× asset turns.

FY26 ROCE is 3%, recovered from a FY21 trough of 0% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): −5.1% net margin × 0.12× asset turns × 1.25× balance-sheet leverage ≈ −0.8% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.19.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Riddhi Siddhi Gluco Biols Ltd carries ₹283 Cr of borrowings against ₹1,509 Cr of equity in FY26, a debt-to-equity of 0.19. Operating profit covers the interest bill −1×. Over 5 years borrowings went from ₹229 Cr to ₹283 Cr. Capital spending ran ₹62.0 Cr across the last 3 of those years.

FY26: borrowings of ₹283 Cr against equity of ₹1,509 Cr — a debt-to-equity of 0.19. Operating profit covers the interest bill −1×. Over 5 years borrowings went from ₹229 Cr to ₹283 Cr while capital spending ran ₹62.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.

→ Who owns this, and are they adding or leaving? Next: Foreign institutions added 2.7 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions added 2.7 points of Riddhi Siddhi Gluco Biols Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 2.7% of the company. Promoters moved +0.5 points over the same window, to 75.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: +2.7 points over 8 quarters to 2.7%; Promoters: +0.5 points over 8 quarters to 75.0%; Domestic institutions: +0.0 points over 8 quarters to 0.0%.

Why the register moved: foreign institutions drove it (+2.7 points), alongside promoters (+0.5 points) — steady accumulation by institutions reading the same numbers this page reads.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Riddhi Siddhi Gluco Biols Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions